和邦生物
(603077)
| 流通市值：183.69亿 | | | 总市值：183.69亿 |
| 流通股本：88.31亿 | | | 总股本：88.31亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,999,261,196.4 | 8,824,107,811.82 | 6,434,462,278.94 | 4,090,613,303.82 |
| 营业收入 | 1,999,261,196.4 | 8,824,107,811.82 | 6,434,462,278.94 | 4,090,613,303.82 |
| 二、营业总成本 | 1,944,326,999.84 | 7,325,629,073.21 | 5,261,021,840.03 | 3,368,929,779.36 |
| 营业成本 | 1,797,137,427.2 | 6,771,569,678.96 | 4,886,566,967.78 | 3,124,929,665.76 |
| 税金及附加 | 11,658,160 | 66,250,890.75 | 43,381,215.69 | 29,132,743.14 |
| 销售费用 | 16,371,720.91 | 59,562,386.76 | 41,065,821.41 | 27,286,146.3 |
| 管理费用 | 106,560,740.12 | 413,402,434.68 | 268,460,823.5 | 173,500,785 |
| 研发费用 | 8,346,347.48 | 47,346,892.37 | 28,642,997.8 | 18,108,486.14 |
| 财务费用 | 4,252,604.13 | -32,503,210.31 | -7,095,986.15 | -4,028,046.98 |
| 其中:利息费用 | 16,275,155.93 | 24,372,822.46 | 42,074,390.08 | 27,129,521.36 |
| 其中:利息收入 | 9,143,232.91 | 60,351,444.11 | 43,564,152.42 | 27,703,996.49 |
| 加:投资收益 | -735,649.12 | 75,219,142.94 | 46,105,613.67 | 42,385,477.43 |
| 资产处置收益 | -46,772.1 | 808,182.23 | 889,135.77 | 4,489.84 |
| 资产减值损失(新) | - | -36,752,062.95 | - | -28,382,477.82 |
| 信用减值损失(新) | -14,527,656.52 | -13,456,089.38 | -21,622,648.41 | -11,584,012.79 |
| 其他收益 | 3,988,080.03 | 17,494,204.69 | 11,790,148.53 | 5,442,280.07 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 43,612,198.85 | 1,541,792,116.14 | 1,210,602,688.47 | 729,549,281.19 |
| 加:营业外收入 | 4.63 | 3,215,517.64 | 41.74 | 34.88 |
| 减:营业外支出 | 3,601.46 | 9,042,112.79 | 763,880.83 | 713,463.72 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 43,608,602.02 | 1,535,965,520.99 | 1,209,838,849.38 | 728,835,852.35 |
| 减:所得税费用 | 16,465,391.27 | 257,266,260.36 | 195,763,416.26 | 125,693,957.24 |
| 六、净利润 | 27,143,210.75 | 1,278,699,260.63 | 1,014,075,433.12 | 603,141,895.11 |
| 持续经营净利润 | 27,143,210.75 | 1,278,699,260.63 | 1,014,075,433.12 | 603,141,895.11 |
| 归属于母公司股东的净利润 | 29,792,564.09 | 1,283,243,893.34 | 1,019,044,364.44 | 616,531,723.76 |
| 少数股东损益 | -2,649,353.34 | -4,544,632.71 | -4,968,931.32 | -13,389,828.65 |
| (一)基本每股收益 | 0 | 0.15 | 0.12 | 0.07 |
| (二)稀释每股收益 | 0 | 0.15 | 0.12 | 0.07 |
| 八、其他综合收益 | 1,488,590.74 | 31,687,239.44 | -61,744.18 | 14,074,680.68 |
| 归属于母公司股东的其他综合收益 | 1,311,974.79 | 28,964,431.54 | -5,852,663.37 | 7,380,745.67 |
| 九、综合收益总额 | 28,631,801.49 | 1,310,386,500.07 | 1,014,013,688.94 | 617,216,575.79 |
| 归属于母公司股东的综合收益总额 | 31,104,538.88 | 1,312,208,324.88 | 1,013,191,701.07 | 623,912,469.43 |
| 归属于少数股东的综合收益总额 | -2,472,737.39 | -1,821,824.81 | 821,987.87 | -6,695,893.64 |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-21 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |